Renal Function Post Cardioversion for Atrial Fibrillation
NCT ID: NCT02742207
Last Updated: 2019-08-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
150 participants
OBSERVATIONAL
2018-07-11
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this prospective study the investigators aim to evaluate the risk of acute renal failure post cardioversion. In addition the investigators would like to evaluate hemodynamic changes, fluid balance and sodium levels in patients post cardioversion as a potential mechanism for both acute renal failure and pulmonary edema post cardioversion. In order to assess hemodynamic changes the investigators will use a non-invasive FDA approved device called NICaS (Non-Invasive Cardiac System). This system calculates cardiac output, cardiac index and peripheral vascular resistance in a non-invasive, fast and accurate way.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Renal Denervation on Atrial Fibrillation
NCT04055285
Rate Control Versus Rhythm Control For Postoperative Atrial Fibrillation
NCT02132767
Safety of Cardioversion of Acute Atrial Fibrillation
NCT01380574
Potassium Infusion for Conversion of Atrial Fibrillation/-Flutter
NCT01818583
Ablation of Atrial Fibrillation in Heart Failure Patients
NCT03062241
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Observational
All comers with Atrial fibrillation
Electrical atrial fibrillation Cardioversion
Electrical cardioversion for patients admitted for Atrial Fibrillation
Cardioversion
Electrical cardioversion for patients admitted for Atrial Fibrillation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Electrical atrial fibrillation Cardioversion
Electrical cardioversion for patients admitted for Atrial Fibrillation
Cardioversion
Electrical cardioversion for patients admitted for Atrial Fibrillation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hadassah Medical Organization
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Dan Gilon
Director, Non-Invasive Cardiology/Echocardiography
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hadassah Medical Organization
Jerusalem, , Israel
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Role: backup
References
Explore related publications, articles, or registry entries linked to this study.
Hellman Y, Cohen MJ, Leibowitz D, Loncar S, Gozal D, Haviv YS, Haber G, Afifi M, Rosenheck S, Lotan C, Pollak A, Gilon D. The incidence and prognosis of renal dysfunction following cardioversion of atrial fibrillation. Cardiology. 2013;124(3):184-9. doi: 10.1159/000346618. Epub 2013 Mar 9.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HMO-15-0645
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.